Tue, Aug 4, 2015
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

Guggenheim takes a closer look at event driven managers

Thursday, October 17, 2013

amb
Charles Stucke
Bailey McCann, Opalesque New York:

Charles Stucke is the Chief Investment Officer of Guggenheim Investment Advisors. He joined the firm in 2006, after building a career as an investment banker. Within his role at Guggenheim he oversees a suite of fund of funds and a hedge fund platform. In a recent Opalesque TV interview, he noted that the firm is shifting its focus, to look at more event driven managers for opportunities over the next two to five years.

"Mid to late 2012, earnings began to mean revert, ROEs began to fall, and yet at the same time, credit prices, or the cost of financing remains very low. So we believe that corporate CFOs would be very tempted to use leverage and do other types of corporate event transactions to maintain or continue to grow earnings and ROEs in an environment that’s becoming increasingly competitive for them. These events include things like restructurings, shared buybacks, recapitalizations and mergers and acquisitions," he explains.

Going forward, investors that are looking to capture the same rate of return from their allocations to equities or fixed income will face some challenges. For Stucke, this means refining focus – "where do you go? You have to find more specific and more active uses of risk to be able to bridge that return goal. So we are looking in places like event strategies, we are looking in long-short equity, we a......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Activist News - Celgene says patent-fighting hedge fund manager wants to short its shares[more]

    From Reuters.com: Celgene Corp, one of the world's largest biotechnology companies, has accused U.S. hedge fund manager Kyle Bass of attempting to profit from his attempts to wipe out several major drug patents through his Coalition for Affordable Drugs. The company asked the U.S. Patent and T

  2. Einhorn's Greenlight Capital hedge fund slumps 6.1 percent in July[more]

    From Reuters/Thefiscaltimes.com: Hedge fund mogul David Einhorn's Greenlight Capital slumped 6.1 percent in July and is now down 9 percent for the year after gold, one of the fund's top holdings, tumbled to five-year lows last week. Greenlight notified clients of its returns late on Friday, ac

  3. Performance - Some hedge fund small-cap energy stocks have been free falling, Dan Loeb's simple strategy destroys the market, Baupost lost 1.4% last quarter as energy bargains proved elusive[more]

    Some hedge fund small-cap energy stocks have been free falling From Marketrealist.com: According to a July 28, 2015, Bloomberg article, there was a 34% fall in small-cap energy stocks over the past three months. These shares are tracked by the Russell 2000 Energy Index. Small-cap energy

  4. Legal - Hedge funds hit Rothstein Kass with $75m malpractice suit, JPMorgan questioned on private bank’s hedge fund disclosures, Kijani fund, seized by regulators in Cayman Islands, spotlights risks in lightly regulated market[more]

    Hedge funds hit Rothstein Kass with $75m malpractice suit From Law360.com: Two investment funds have sued Rothstein Kass & Co. PC for at least $75 million, claiming the New Jersey auditing firm committed accounting malpractice by failing to properly scrutinize overblown valuations of the

  5. Assets - Hedge funds are getting smoked by the commodities slump, Global ETF assets could more than double by 2020[more]

    Hedge funds are getting smoked by the commodities slump From Businessinsider.in: The collapse in commodity prices has burnt another hedge fund. Vermillion, a commodity hedge fund backed by Carlyle Group, has seen its flagship fund's assets fall from nearly $2 billion to less $50 million,

 

banner